NLRP3 inhib 
Welcome,         Profile    Billing    Logout  
 7 Companies  6 Products   6 Products   29 Diseases   11 Trials   763 News 


«12...8889909192939495969798...134135»
  • ||||||||||  simvastatin / Generic mfg.
    Journal:  Endothelial Foxp1 Suppresses Atherosclerosis via Modulation of Nlrp3 Inflammasome Activation. (Pubmed Central) -  Jul 9, 2020   
    These data are the first in vivo experimental validation of an atheroprotective role of endothelial Klf2 and Foxp1, which reveals a Klf2-Foxp1 transcriptional network in ECs as a novel regulator of endothelial inflammasome activation for atherogenesis, therefore provides opportunities for therapeutic intervention of atherosclerotic diseases and uncovers a novel atheroprotective mechanism for simvastatin.
  • ||||||||||  Journal:  Control of the inflammasome by the ubiquitin system. (Pubmed Central) -  Jul 9, 2020   
    However, the mechanisms by which PTMs regulate the inflammasome is still not understood. This review aims to summarize our knowledge to date on how the ubiquitin system controls inflammasome activation and where this area of research is heading.
  • ||||||||||  Review, Journal:  The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney. (Pubmed Central) -  Jul 9, 2020   
    Inflammasome-independent NLRP3 regulates apoptosis in tubular epithelial cells by interacting with mitochondria and mediating mitochondrial reactive oxygen species production and mitophagy. This review will summarize the mechanisms by which NLRP3 functions in the kidney in both inflammasome-dependent and inflammasome-independent ways and the role of NLRP3 and NLRP3 inhibitors in kidney diseases.
  • ||||||||||  Journal:  Altered monocyte response to the dengue virus in those with varying severity of past dengue infection. (Pubmed Central) -  Jul 8, 2020   
    Further studies are warranted to address potential adverse outcomes of coronavirus disease 2019 in patients with CHIP-driver sequence variations. Monocytes from those with past SD appear to show marked differences in viral loads, viral sensing and production of inflammatory mediators in response to the DENV, when compared to those who experienced past NSD, suggesting that initial innate immune responses may influence the disease outcome.
  • ||||||||||  Review, Journal:  CAPS and NLRP3. (Pubmed Central) -  Jul 7, 2020   
    Several mechanisms have been identified that are important for the normal regulation of the cryopyrin inflammasome in order to prevent uncontrolled inflammation. Investigators have taken advantage of some of these pathways to develop and apply novel targeted therapies, which have resulted in improved quality of life for patients with this orphan disease.
  • ||||||||||  Biomarker, Journal:  Role of serum amyloid A in atherosclerosis. (Pubmed Central) -  Jul 7, 2020   
    Investigators have taken advantage of some of these pathways to develop and apply novel targeted therapies, which have resulted in improved quality of life for patients with this orphan disease. SAA has many pro-inflammatory and pro-atherogenic activities, is clearly demonstrated to affect atherosclerosis development, and may be a candidate target for clinical trials in cardiovascular diseases.
  • ||||||||||  allopurinol / Generic mfg.
    Review, Journal:  Gout. (Pubmed Central) -  Jul 7, 2020   
    Low-dose anti-inflammatory therapies can reduce gout flares during initiation of urate-lowering therapy. Models of care, such as nurse-led strategies that focus on patient engagement and education, substantially improve clinical outcomes and now represent best practice for gout management.
  • ||||||||||  Journal:  SUMO1 SUMOylates and SENP3 deSUMOylates NLRP3 to orchestrate the inflammasome activation. (Pubmed Central) -  Jul 7, 2020   
    Interestingly, SENP3 deSUMOylates NLRP3 to attenuate ASC recruitment and speck formation, the NLRP3 inflammasome activation, as well as IL-1β cleavage and secretion. In conclusion, we reveal that SUMO1-catalyzed SUMOylation and SENP3-mediated deSUMOylation of NLRP3 orchestrate the inflammasome activation.
  • ||||||||||  Clinical, Review, Journal:  Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. (Pubmed Central) -  Jul 7, 2020   
    There are no evidence-based studies to establish which potential genotype analysis is the most appropriate in adult patients with clinical phenotypes suggestive of mAIDs. This review discusses genetic and clinical hints for an ideal diagnostic approach to mAIDs in adult patients, as their early identification is essential to prompt effective treatment and improve quality of life, and also highlights the most recent developments in the diagnostic work-up for the most frequent hereditary periodic febrile syndromes worldwide.
  • ||||||||||  Preclinical, Journal:  Genistein Attenuates Acute Cerebral Ischemic Damage by Inhibiting the NLRP3 Inflammasome in Reproductively Senescent Mice. (Pubmed Central) -  Jul 7, 2020   
    However, the overexpression of NLRP3 in microglia abrogated the Gen-induced inhibition of inflammatory factor release and reversed the neuroprotective effect of Gen. Taken together, the results suggest that Gen treatment could attenuate the acute injury induced by cerebral ischemia in reproductively senescent mice via the inhibition of the NLRP3 inflammasome in microglia, indicating that Gen could be a candidate drug for the treatment of stroke in postmenopausal women.
  • ||||||||||  [VIRTUAL] TREK-1 Activation Is Required for Inflammasome Activity Through Augmentation of Macrophage Membrane Polarization (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_7342;    
    Taken together, the results suggest that Gen treatment could attenuate the acute injury induced by cerebral ischemia in reproductively senescent mice via the inhibition of the NLRP3 inflammasome in microglia, indicating that Gen could be a candidate drug for the treatment of stroke in postmenopausal women. Our results suggest that TREK-1 is important in regulating macrophage membrane potential, and may be important in regulating potassium-efflux associated with inflammasome activity.
  • ||||||||||  [VIRTUAL] Trim20/Pyrin Regulates Microparticulate Active GasderminD Mediated Cell Injury in Septic Patients (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_5954;    
    Phosphorylated pyrin was detected along with serine/threonine kinase PKN1, active caspase-1 and GSDM-D in MPs derived from LPS stimulated THP1 cells. The protein interacting regulatory molecule 14-3-3, bound phosphorylated pyrin and this association was abrogated by knocking down upstream NLRP3 but not affected by inhibition of downstream caspase-1.
  • ||||||||||  [VIRTUAL] Long Form of Thymic Stromal Lymphopoietin Aggravates Pyroptosis of Human Airway Epithelium on Virus-Induced Asthma Exacerbation (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4864;    
    lfTSLP aggravated the activation of NLRP3 inflammasome ,the cleavage of GSDMD and the release of mature IL-1β in HDM-sensitized epithelial cells induced by poly(I:C),thus promoting epithelium pyroptosis. Consistent with this observation, Mouse TSLP expression, the ortholog of human lfTSLP, was found to be critical for the dysfunction of bronchial epithelial barrier and airway inflammation in murine model of viral asthma exacerbation, which could be suppressed by administration of TSLP mAb or human short form of thymic stromal lymphopoietin(sfTSLP).
  • ||||||||||  bleomycin / Generic mfg., BMS, sildenafil / Generic mfg.
    [VIRTUAL] Targeting the NLRP3 Inflammasome as a Novel Approach to Treat Pulmonary Hypertension (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4705;    
    Interventions commenced at day 14 (SuHx) or 7 (BLM) and included: NLRP3 inflammasome inhibitor MCC950 (10mgkg/day [low] or 20mg/kg/day [high]; s.c.), current therapy sildenafil (SILD; 30mg/kg/day; p.o.) or combination therapy (MCC950 10mg/kg/day + SILD)...Further, initial evidence suggests that IL-18 receptor signalling may be vital for SuHx-induced increases in RVSP. This highlights a previously unrecognised therapeutic option whereby selective targeting of the NLRP3 inflammasome, or its downstream cytokine IL-18, may provide a novel adjunct to current pulmonary vasodilator therapy.
  • ||||||||||  [VIRTUAL] The NLRP3 Inflammasome in the Cystic Fibrosis Macrophage (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_970;    
    The variant was associated with greater IL-6 production in response to lipopolysaccharide, suggesting the possibility of crosstalk between inflammasome and non-inflammasome-mediated pathways. Our finding identifies a subset of people with CF who could benefit most from host-directed therapeutics targeting inflammasome pathways.
  • ||||||||||  [VIRTUAL] Gasdermin D: A New Biomarker for Critically Ill Patients (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_901;    
    Furthermore, GSDMD correlates with other pyroptotic effector molecules, namely IL-18. These results suggest pyroptosis, through interaction with other cell death pathways, may play a critical role in the dysregulated immune response in sepsis.
  • ||||||||||  Journal:  The activation of IL-17 signaling pathway promotes pyroptosis in pneumonia-induced sepsis. (Pubmed Central) -  Jul 5, 2020   
    Moreover, the release of IL-1β and IL-18 and the levels of the molecules (NLRP3, NLRC4, Cleaved caspase-1, and Cleaved GSDMD) associated with caspase-1-dependent pyroptosis were up-regulated in pneumonia-induced sepsis. As NK-κB activation can promote the development of caspase-1-dependent pyroptosis, these findings suggested that the activation of the IL-17 signaling pathway could promote pyroptosis in pneumonia-induced sepsis.
  • ||||||||||  Review, Journal:  P2X7 receptor in cardiovascular disease: The heart side. (Pubmed Central) -  Jul 4, 2020   
    Recent studies demonstrated that the P2X7 could modulate the assembly of the NLRP3 inflammasome, leading to the secretion of pro-inflammatory factors and worsen the cardiac disease phenotypes. This review discusses the critical molecular function of P2X7 in the modulation of the onset, progression and resolution of cardiovascular diseases and analyses the putative future use of P2X7-based therapies that modulate the IL-1β secretion arm and direct P2X7 antagonists.